Researchers presented these bladder cancer study findings at the 117th Annual Scientific Meeting of the American Urological Association (AUA)
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Results support the development of tislelizumab in potentially synergistic combinations across Novartis advanced therapeutic platforms for the treatment of an array of solid tumours
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
Subscribe To Our Newsletter & Stay Updated
